PINX:HEWA Quarterly Report 10-Q Filing - 3/31/2012

Effective Date 3/31/2012

PINX:HEWA (): Fair Value Estimate
Premium
PINX:HEWA (): Consider Buying
Premium
PINX:HEWA (): Consider Selling
Premium
PINX:HEWA (): Fair Value Uncertainty
Premium
PINX:HEWA (): Economic Moat
Premium
PINX:HEWA (): Stewardship
Premium
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
________________________________
 
FORM 10-Q
 (Mark One)
 
x
QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended March 31, 2012
 
¨
TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from              to             

Commission File Number 0-13117

HealthWarehouse.com, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
 
22-2413505
(State or Other Jurisdiction
 
(I.R.S. Employer
of Incorporation or Organization)
 
Identification No.)
 

7107 Industrial Road, Florence,Kentucky
41042
(Address of Principal Executive Offices)
(Zip Code)

(513) 618-0911
(Registrant’s Telephone Number, Including Area Code)

(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)
 

Indicate  by check mark whether the registrant (1) has filed all reports required to be  filed by Section 13 or 15(d) of the Exchange Act of 1934 during the past 12 months (or  for such  shorter  period  that  the  registrant  was required to file such reports), and  (2) has  been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).     Yes  x     No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
 
Large Accelerated Filer o                                                                       Accelerated Filer                       o
 
Non-accelerated Filer o                                                                           Smaller Reporting Company   x
(Do not check if a smaller reporting company)
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x

There were 11,743,611 shares of Common Stock outstanding as of August 10, 2012.
 
 
 
 

 

 
HEALTHWAREHOUSE.COM, INC.

QUARTERLY REPORT ON FORM 10-Q
FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2012
 
 

 
Page
   
PART I. FINANCIAL INFORMATION
 
   
ITEM 1.
3
     
ITEM 2.
13
     
ITEM 3.
17
     
ITEM 4.
17
     
PART II. OTHER INFORMATION
 
   
ITEM 1.
20
     
ITEM 1A.
20
     
ITEM 2.
20
     
ITEM 3.
20
     
ITEM 4.
20
     
ITEM 5.
20
     
ITEM 6.
20
     
 
21
 
 
 
 
 
 

 


 
 
 
PART I. FINANCIAL INFORMATION

 
HEALTHWAREHOUSE.COM, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS

Assets
 
   
March 31, 2012
(unaudited)
   
December 31, 2011
 
Current assets
           
Cash
  $ 3     $ 40  
Accounts receivable, net
    188,563       220,626  
Inventories – finished goods, net
    447,691       553,897  
Employee advances
    379,750       298,707  
Prepaid expenses and other current assets
    37,094       54,480  
      Total current assets
    1,053,101       1,127,750  
Property and equipment, net
    873,956       943,849  
Intangible assets, net of accumulated amortization of $161,778 and $90,794 as
       of March 31, 2012 and as of  December 31, 2011, respectively
    531,557       602,541  
                 
          Total  assets
  $ 2,458,614     $ 2,674,140  
Liabilities and Stockholders’ Deficiency
 
Current liabilities
           
Accounts payable – trade
  $ 1,837,427     $ 1,547,657  
Accounts payable – related parties
    9,307       14,209  
Cash overdraft
    83,911       239,567  
Accrued expenses and other current liabilities
    429,095       549,011  
Current portion of capital leases
    44,350       3,346  
    Convertible notes, net of deferred debt discount of $192,772 and $275,388,
        as of March 31, 2012 and December 31,2011, respectively
    807,228       724,612  
     Note payable, net of deferred debt discount of $443,646 and $0, as of
        March 31, 2012 and December 31,2011, respectively
    1,556,354       -  
     Note payable and other advances – from stockholders
    765,000       453,812  
Total current liabilities
  $ 5,532,672     $ 3,532,214  
                 
Long term liabilities
               
     Notes payable, net of deferred debt discount of $0 and $576,741 as
         of March 31, 2012 and December 31, 2011, respectively
    -       1,423,259  
     Long term portion of capital leases
    203,649       9,201  
         Total liabilities
    5,736,321       4,964,674  
Commitments and contingencies
               
Redeemable preferred stock – Series C ; net of discount $340,690 and
        $433,606  as of March 31, 2012 and  December 31, 2011, respectively,
        par value $.001 per share; authorized 1,000,000 shares; 10,000 designated
        Series C: 10,000 issued and outstanding  as of March 31, 2012 and
        December 31, 2011(aggregate liquidation preference $1,000,000)
    659,310       566,394  
                 
Stockholders’ deficiency
               
Preferred Stock par value $.001 per share; authorized 1,000,000 shares;
     issued and outstanding as of  March 31, 2012 and December 31, 2011, as follows:
               
Convertible preferred stock - Series A –200,000 shares designated Series A;
    no  shares issued and outstanding
    -       -  
Convertible preferred stock - Series B –625,000 shares designated Series B;
    394,685 and 368,862  shares issued, and outstanding, respectively
    (aggregate liquidation preference $3,729,773)
    395       369  
Common stock – par value $.001 per share; authorized 50,000,000 shares;
11,376,688  and 11,283,830 shares issued, respectively and 10,197,476 and
 10,104,618 shares outstanding, respectively
      11,377         11,284  
Shares issuable
    125,000       -  
Additional paid-in capital
    15,613,634       15,110,343  
Treasury stock, at cost, 1,179,212 shares as of  March 31, 2012 and
     December 31, 2011
    (3,419,715 )     (3,419,715 )
Accumulated deficit
    (16,267,708 )     (14,559,209 )
     Total stockholders’deficiency
    (3,937,017 )     (2,856,928 )
Total liabilities and stockholders’  deficiency
  $ 2,458,614     $ 2,674,140  

The accompanying notes are an integral part of these condensed consolidated financial statements.
 
 
 
 

 
 
 
 
HEALTHWAREHOUSE.COM, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
 
   
For the Three Months
Ended
March 31, 2012
   
For the Three Months
Ended
March 31, 2011
 
             
Net sales
  $ 3,153,607     $ 2,284,552  
                 
Cost of sales
    1,704,647       1,298,143  
Gross profit
    1,448,960       986,409  
                 
Operating expenses:
               
                 
   Selling, general and administrative expenses
    2,684,478       1,953,698  
                 
Loss from operations
    (1,235,518 )     (967,289 )
                 
Other income (expense):
               
Interest income
    2,548       1,162  
Interest expense
    (317,342 )     (105,152 )
    Total other expense
    (314,794 )     (103,990 )
                 
Net loss
  $ (1,550,312 )   $ (1,071,279 )
                 
Preferred Stock:
               
Series B convertible contractual dividends
    (65,271 )     (61,000 )
Series C redeemable deemed dividends
    (92,916 )     -  
                 
Loss attributable to common stockholders
  $ (1,708,499 )   $ (1,132,279 )
                 
Per share data:
               
Net loss per common share - basic and diluted
  $ (0.15 )   $ (0.10 )
Contractual dividends
    (0.01 )     (0.01 )
Deemed dividends
    (0.01 )     -  
Net loss attributable to common stockholders per share – basic and diluted
  $ (0.17 )   $ (0.11 )
                 
Weighted average number of common shares outstanding - basic and diluted
    10,191,353       10,487,046  

 

 
The accompanying notes are an integral part of these condensed consolidated financial statements.




 
 
HEALTHWAREHOUSE.COM, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)


   
For the Three Months
Ended March 31, 2012
   
For the Three Months
Ended March 31, 2011
 
Cash flows from operating activities
           
Net loss
  $ (1,550,312 )   $ (1,071,279 )
Adjustments to reconcile net loss to net cash used in operating activities:
               
Provision for doubtful accounts
    10,521       30,000  
Depreciation and amortization
    111,851       71,009  
Stock-based compensation
    259,409       211,714  
Amortization of deferred debt discount
    215,711       86,775  
Changes in operating assets and liabilities:
               
Accounts receivable
    21,542       (132,814 )
Inventories  - finished goods
    106,206       65,757  
Prepaid expenses and other current assets
    17,386       2,445  
Accounts payable – trade
    550,400       479,359  
Accounts payable – related parties
    (4,902 )     33,850  
Accrued expenses and other current liabilities
    84,793       (124,464 )
Net cash used in operating activities
    (177,395 )     (347,648 )
                 
Cash flow from investing activities
               
         Acquisition of Hocks.com assets
    -       (200,000 )
         Employee advances
    (81,043 )     (6,142 )
         Proceeds from the return of property and equipment
    -       15,732  
         Acquisition of property and equipment
    -       (30,997 )
Net cash used in investing activities
    (81,043 )     (221,407 )
                 
Cash flows from financing activities
               
Principal payments on capital leases
    (22,131 )     -  
Proceeds received for shares issuable
    125,000       -  
Cash overdraft
    (155,656 )     -  
Proceeds from notes payable and other advances – from stockholders
    375,000       -  
Repayment of notes payable and other advances – from stockholders
    (63,812 )     -  
Net cash provided by financing activities
    258,401       -  
                 
Net decrease in cash
    (37 )     (569,055 )
                 
Cash - beginning of  period
    40       1,397,583  
                 
Cash - end of period
  $ 3     $ 828,528  
                 
Cash paid for:
               
     Interest
  $ 21,491     $ 9,117  
     Taxes
  $ -     $ -  
                 
Non-cash investing and financing activities                
Conversion of convertible notes into common stock
  $ -     $ 200,000  
Exchange of common stock to acquire assets of Hocks.com
  $ -     $ 693,335  
Issuance of series B preferred stock for settlement of accrued dividends
  $ 244,001     $ 33,992  
Cashless exercise of options into common stock
  $ 93     $ -  
Accrued dividends
  $ 65,271     $ 61,000  
Reclassification of accounts payable – trade to capital lease payable
  $ 257,583     $ -  
Deemed dividend – redeemable series C preferred stock
  $ 92,916     $ -  
                 
Purchase price allocation:
               
Current assets – Inventory
  $ -     $ 200,000  
Customer relationships
  $ -     $ 693,335  
Net fair value of assets acquired/Total purchase price
  $ -     $ 893,335  


The accompanying notes are an integral part of these condensed consolidated financial statements.






HEALTHWAREHOUSE.COM, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(unaudited)

1.  Organization and Basis of Presentation

 
HealthWarehouse.com, Inc. (the “Company”) is a U.S. licensed virtual retail pharmacy (“VRP”) and healthcare e-commerce company that sells brand name and generic prescription drugs as well as over-the-counter (“OTC”) medical products. The Company’s objective is to be viewed by individual healthcare product consumers as a low-cost, reliable and hassle-free provider of prescription drugs and OTC medical products. The Company is presently licensed as a mail-order pharmacy for sales to 50 states and the District of Columbia.
 
The condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for certain financial information and the instructions to Form 10-Q and Article 10 of the Regulation S-X. Accordingly, the condensed consolidated balance sheet as of March 31, 2012 and the condensed consolidated statements of operations and cash flows for the three months ended March 31, 2012 and 2011, have been prepared by the Company without being audited. In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to make the Company’s condensed consolidated financial position, results of operations and cash flows at March 31, 2012 not misleading have been made. The condensed consolidated results of operations for the three months ended March 31, 2012 are not necessarily indicative of results that would be expected for the full year or any other interim period.
 
Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and notes thereto included in the current report on Form 10-K filed with the Securities and Exchange Commission on June 22, 2012.
 
2. Management’s Liquidity Plans

Since inception, the Company has financed its operations primarily through product sales to customers, debt and equity financing agreements, and advances from stockholders. As of March 31, 2012 and December 31, 2011, the Company had negligible cash and a working capital deficiency of $4,479,571 and $2,404,464, respectively.  For the three months ended March 31, 2012, cash flows included net cash used in operating activities of $177,395, net cash used in investing activities of $81,043 and net cash provided by financing activities of $258,401. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.

Management believes that the Company has taken certain steps to improve its operations and cash flows, including improved inventory purchasing and an increase in the number of suppliers. In addition, with the acquisition of Hocks.com, during 2011, the Company significantly increased its revenues and improved its gross margin. Management believes that these steps will increase its chances for success; however, there can be no such assurance.

During the three months ended March 31, 2012, the Company received advances of $375,000 from certain stockholders and repaid $63,812 of such advances. In addition, the Company received $125,000 in cash during the quarter for common stock which has been included in shares issuable on the condensed consolidated balance sheet at March 31, 2012, as the shares were not issued by that date. The Company recognizes it will need to raise additional capital in order to reduce its debt, meet operations and execute its business plan. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company and whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to develop and implement a plan to further extend payables and reduce overhead until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful.
 
 
 
 
 

 
 
 
Accordingly, the accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern and the realization of assets and the satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the condensed consolidated financial statements do not necessarily represent realizable or settlement values. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

3. Summary of Significant Accounting Policies
 
Principles of Consolidation

The condensed consolidated financial statements include the accounts of HealthWarehouse.com, Inc., Hwareh.com, Inc., Hocks.com, Inc., ION Holding NV, and ION Belgium NV, its wholly-owned subsidiaries. ION Holding NV and ION Belgium NV are inactive subsidiaries. All material inter-company balances and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.  The Company’s significant estimates include reserves related to accounts receivable and inventory, the recoverability and useful lives of long-lived assets, the valuation allowance related to deferred tax assets, the valuation of equity instruments and debt discounts.
 
 
 Net Loss Per Share of Common Stock
 
Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period.  Diluted net loss per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock.  Potentially dilutive securities are excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive and consist of the following:

   
March 31, 2012
   
March 31, 2011
 
             
Options
    2,033,807       2,263,800  
Warrants
    2,916,590       1,915,340  
Series B Convertible Preferred Stock
    1,973,425       1,844,310  
Convertible Promissory Notes
    529,100       12,500  
Totals
    7,452,922       6,035,950  
 
 
 
 
 
 

 
Stock-Based Compensation

Stock-based compensation expense for all stock-based payment awards is based on the estimated grant-date fair value. The Company recognizes these compensation costs over the requisite service period of the award, which is generally the option vesting term.  Option valuation models require the input of highly subjective assumptions including the expected life of the option. During the period ended June 30, 2011 and prior periods, the fair value of stock-based payment awards was estimated using the Black-Scholes option model with a volatility figure derived from an index of historical stock prices of comparable entities until sufficient data existed to estimate the volatility using the Company’s own historical stock prices.  Beginning July 2011, the Company began to use the historical trading prices of its own common stock as a component in the calculation of an estimated volatility figure to determine the fair value of stock-based payment awards using the Black-Scholes model. Management determined this assumption to be a better indicator of value. The Company accounts for the expected life of options in accordance with the “simplified” method which enables the use of the simplified method for “plain vanilla” share options as defined in Staff Accounting Bulletin No. 107.

Stock-based compensation for the three months ended March 31, 2012 and 2011 was recorded in the condensed consolidated statements of operations as a component of selling, general and administrative expenses and totaled $259,409 and $ 211,714, respectively.

As of March 31, 2012, stock compensation of approximately $1,800,000 remains unamortized and is being amortized on a straight-line basis over three years from the date of grant.

The fair value of stock-based payment awards was estimated using the Black-Scholes pricing model with the following assumptions and weighted average fair values ranges as follows:

   
For the Three Months Ended
March 31, 2012
   
For the Three Months Ended March 31, 2011
 
Risk-free interest rate
    1.04 %     2.72 %
Dividend yield
    N/A       N/A  
Expected volatility
    172.2 %     55.2 %
Expected life in years
    6.00       6.00  

4. Stockholders’ Deficiency

Common Stock

During the three months ended March 31, 2012, the Company entered into securities purchase agreements with investors who agreed to invest an aggregate of $125,000 for 27,779 shares of common stock at $4.50 per share. The Company received $125,000 in cash proceeds and recorded the transaction as shares issuable since the shares had not been issued as of March 31, 2012 due to delays in issuing the stock certificates.

Preferred Stock

On January 1, 2012, the Company issued 25,823 shares of Series B convertible preferred stock valued at $244,001 to the Series B convertible preferred stock owners as payment in kind for dividends. Additionally, during the three months ended March 31, 2012, the Company recorded $65,271 and $92,916 as contractual and deemed dividends, respectively, in connection with the outstanding preferred stock.

Stock Options
 
On January 6, 2012, the Company’s Chief Financial Officer was issued 92,858 shares of common stock per a cashless exercise of a stock option with an exercise price of $0.80 to purchase 105,450 shares of common stock.
 
 
 
 
 
 
 

 
On March 30, 2012, the Company granted four Directors options to purchase an aggregate of 60,000 shares of common stock under a previously approved plan with an exercise price of $6.99, which is the approximate fair value of a share of common stock on the grant date.  The options have an aggregate grant date fair value of $391,028, vest over a three year period and have a term of ten years.

On March 30, 2012, the Company granted employees options to purchase an aggregate of 30,000 shares of common stock under a previously approved plan with an exercise price of $6.99, which is the approximate fair value of a share of common stock on the grant date.  The options have an aggregate grant date fair value of $195,514, vest over a three year period and have a term of ten years.
 
Details of the options outstanding under all plans are as follows:

   
Shares
   
Weighted Average
Exercise Price
   
Weighted- Average
Remaining
Contractual
Term
   
Aggregate
Intrinsic
Value
 
                                 
Options outstanding at January 1, 2012
    2,165,925     $ 2.89       6.25       -  
Granted
    90,000     $ 6.99       --       -  
Expired
    --       --       --       -  
Canceled
    (116,668 )   $ 3.97       --       -  
Exercised 
    (105,450 )   $ 0.80       --       -  
Options outstanding at March 31, 2012
    2,033,807     $ 3.11       6.22     $ 7,403,655  
Options exercisable at March 31, 2012
    835,471     $ 2.24       5.24     $ 3,764,194  
 
Range of Exercise
 
Number
Outstanding
   
Weighted Average
Remaining Years of
Contractual Life
   
Weighted Average
Exercise Price
   
Number
Exercisable
   
Weighted Average
Exercise Price
 
                               
$0.80 – 2.00
    253,475       5.05     $ 0.92       236,349     $ 0.88  
$2.00 – 6.99
    1,780,332       6.19     $ 3.43       599,122     $ 2.78  
$0.80 – $6.99
    2,033,807       6.05     $ 3.11       835,471     $ 2.24  

5. Commitments and Contingent Liabilities

Operating Leases

The Company’s leasehold interest in its office and warehouse space was subject to a mechanic’s lien in favor of the contractor that assisted with the construction of the facility. The amount the Company owed to the contractor was in dispute. On June 14, 2012, the Company reached a written settlement and agreed to pay the contractor the total amount of $189,000. The Company received a general release and release of mechanic’s lien from the contractor, which will be effective upon final payment. Approximately, $140,000 and an additional $46,000 in interest is included in accounts payable as of March 31, 2012.
 
 

 


 

 

During the three months ended March 31, 2012 and 2011, the Company recorded rent expense of $52,457 and $38,375, respectively.

Capital Leases

At December 31, 2011, the Company had $257,583 included in accounts payable - trade relating to certain equipment acquired. In January 2012, the Company renegotiated the terms of the payable into a lease agreement for the same equipment. The lease term is five years with a principal amount of $257,583 and an effective interest rate of 14.7% per annum.

Future minimum lease payments, by year and in the aggregate, under capital leases as of March 31, 2012 are as follows:

For year ending December 31
 
Amortization
 
       
2012
  $ 57,546  
2013
    76,757  
2014
    76,727  
2015
    75,892  
Thereafter
    48,949  
Total
    335,871  
         
Less: amount representing interest
    87,872  
         
Present value of  future minimum lease payments
  $ 247,999  
 
As of March 31, 2012, the equipment has a net book value of $283,817, as additional costs were incurred and capitalized but not financed. Depreciation of assets held under capital leases in the amount of $5,094 is included in depreciation expense for the three months ended March 31, 2012.

Litigation

On November 29, 2011, NMN Advisors, Inc. (“Plaintiff”) filed a complaint against the Company alleging that it breached a consulting agreement.   The complaint seeks damages of $70,000 plus pre-judgment interest.   On February 6, 2012, the Company filed its answer to the complaint denying that the Company owes any amounts under the contract, and the Company also filed a cross-complaint against the plaintiff asserting a number of causes of action, including breach of contract.  Plaintiff filed its answer to the Company cross-complaint on March 5, 2012.  Both the Company and the Plaintiff agreed to attempt to resolve the dispute by court mediation and on August 21, 2012, the Company paid $35,000 in full settlement of all outstanding balances.

On February 9, 2012, two of the Company’s former stockholders, Rock Castle and Jason Smith (“Plaintiffs”), filed suit against the Company in the Hamilton County, Ohio Court of Common Pleas, alleging that the Company had breached the terms of certain incentive options the Company granted to the Plaintiffs in connection with the Company’s now-terminated oral consulting arrangements with the Plaintiffs, by among other things, refusing Plaintiffs’ purported exercise of options to purchase 233,332 shares of the Company’s common stock at an exercise price of $2.00 per share in December 2011.  Plaintiffs have not specified monetary damages, but have requested that, among other things, the court require the Company to permit the exercise of the 233,332 options.  The Company believes all of the Plaintiffs’ claims are without merit.  On March 13, 2012, the Company moved to dismiss all claims asserted against the Company in the Complaint.  On July 24, 2012 the Company filed a counter claim against the defendant.
 
 
 
 
 
 
- 10 -

 
 

 
On March 2, 2012, a former contractor filed suit against the Company in the Hamilton County, Ohio Court of Common Pleas, alleging that, among other things, the Company had failed to pay amounts due on certain credit cards that were issued in plaintiff’s name but for which the Company agreed to assume financial responsibility.  Although the Company denies any responsibility for the payments owed, the Company resolved this dispute by entering into a settlement agreement with the plaintiff, and the suit was voluntarily dismissed on May 30, 2012. The settlement amount of $31,321 was included in accounts payable as of March 31, 2012.

In the normal course of business the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. Currently, the Company is not involved in any such matters.

6. Concentrations

During the three months ended March 31, 2012, one vendor represented 40.5% of total purchases.

7. Related Party Transactions

Between June 2009 and April 2012, an employee who is the son of the managing member of a limited liability company that beneficially owns approximately 12% of the Company’s common stock received advances from the Company in various forms, including the provision of fulfillment services at no charge to a business partly owned by a member of his household. As of March 31, 2012, the balance of these advances totaled $373,250. The Company’s board of directors determined that not all of these advances were approved in accordance with the Company’s policy on related party transactions, documented appropriately or recorded correctly in the Company’s accounting system. As a result, the Company was not able to monitor the outstanding amount of these advances on a continuous basis. This employee has voluntarily resigned from the Company, made principal repayments of $235,000 through the date of this report, and agreed to repay the remaining balance by September 30, 2012 with interest based on prime rate on the business day of the calendar quarter, and provided security for his repayment obligation.

8. Acquisition of Hocks

On February 14, 2011, Hocks Acquisition Corporation (“Hocks Acquisition”), the Company’s wholly-owned subsidiary, entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Hocks Pharmacy Inc., an Ohio corporation (“Hocks Pharmacy”) and its stockholders.  Under the Asset Purchase Agreement, Hocks Acquisition purchased all of the inventory and fixed assets (the “Purchased Assets”) owned by Hocks Pharmacy and used in the operation of its internet pharmacy business (the “Internet Business).  The Internet Business consists primarily of the internet sale of over-the-counter health and medical products and supplies.
 
During the three months ended March 31, 2011, for the months of February and March, the Company recognized $636,204 of revenue generated by Hocks.com.
 
The following table presents the unaudited pro-forma combined results of operations of the Company and Hocks.com for the three months ended March 31, 2011 as if Hocks.com had been acquired at the beginning of that period.
 
   
For the three months 
ended March 31, 2011
(unaudited)
 
       
       
Revenue
  $ 2,618,506  
         
Net loss
  $ (1,078,476  
         
Pro-forma basic and diluted net loss per common share
  $ (0.10 )
 
       
Weighted average common shares outstanding – basic and diluted
    10,653,713  

 
 
 
 
 
- 11 -


 
 
 
9. Subsequent Events
 
Management has evaluated subsequent events or transactions occurring through the date on which the condensed consolidated financial statements were issued.

Subsequent to March 31, 2012, the Company issued an aggregate of 94,448 shares of common stock at a per share price of $4.50. Of the aggregate proceeds of $425,004, $125,000 was received during the three months ended March 31, 2012 and classified as shares issuable at March 31, 2012.

Subsequent to March 31, 2012, the Company issued 8,332 shares of common stock in connection with the exercise of options to purchase common stock with exercise prices between $2.80 to $3.60 per share receiving total proceeds of $26,662.
 
Subsequent to March 31, 2012, the Company received aggregate proceeds of $50,000 for the purchase of 11,112 shares of common stock at a per share price of $4.50.  As of the date of this report the Company has not issued such shares.

Subsequent to March 31, 2012, three holders of warrants issued to them in connection with prior equity or debt financing transactions elected to exercise all of their warrants on a “cashless” basis under the terms of the warrants. Warrants to purchase a total of 2,353,744 were exercised. HWH Lending, LLC received a total of 716,484 net shares of common stock from the cashless exercise. Milfam I, L.P. received a total of 716,484 net shares of common stock from the cashless exercise. A third accredited investor received a total of 32,610 net shares of common stock from the cashless exercise. The warrants had exercise prices of $1.60 per share (471,628 net shares), $3.00 per share (701,388 net shares) and $2.90 per share (292,562 net shares).
 
Subsequent to March 31, 2012, the Company received advances from certain stockholders aggregating $220,000 which has been repaid as of the date of this report.
 
 
 
 
 
 

 
 
- 12 -



 
 

Overview
 
We are a licensed U.S. pharmacy and healthcare e-commerce company that sells discounted brand name and generic prescription drugs and over-the-counter (OTC) medical products. Our web address is http://www.healthwarehouse.com. At present, we sell:
 
·  
a range of prescription drugs;
 
·  
diabetic supplies including glucometers, lancets, syringes and test strips;
 
·  
OTC medications covering a range of conditions from allergy and sinus to pain and fever to smoking cessation aids;
 
·  
home medical supplies including incontinence supplies, first aid kits and mobility aids; and
 
·  
diet and nutritional products including supplements, weight loss aids, and vitamins and minerals.
 
Our objective is to make the pharmaceutical supply chain more efficient by eliminating costs and passing on the savings to the consumer.  We are becoming known by consumers as a convenient, reliable, discount provider of over the counter and prescription medications and products. We intend to continue to expand our product line as our business grows. We are presently licensed as a mail-order pharmacy for sales to all 50 states and the District of Columbia.

Results of Operations
 
The three months ended March 31, 2012 compared to the three months ended March 31, 2011
 
   
The three months
ended
March 31, 2012
   
% of
Revenue
   
The three months
ended
March 31, 2011
   
% of
Revenue
 
                         
Revenue
  $ 3,153,607       100.0 %   $ 2,284,552       100.0 %
Cost of sales
    1,704,647       54.1 %     1,298,143       56.8 %
Gross profit
    1,448,960       45.9 %     986,409       43.2 %
Selling, general & administrative  expenses
    2,684,478       85.1 %     1,953,698       85.5 %
Loss from operations
    (1,235,518 )     (39.2 )%     (967,289 )     (42.3 )%
Interest income
    2,548       0.1 %     1,162       0.1 %
Interest expense
    (317,342 )     (10.1 )%     (105,152 )     (4.6 )%
Net loss
  $ (1,550,312       (49.2 )%   $ (1,071,279 )     (46.9 )%
 
Revenue
 
   
The three months
ended
March 31, 2012
   
% Change
   
The three months
ended
March 31, 2011
 
Total revenue
 
$
3,153,607
     
38.0%
   
$
2,284,552
 
Total average net sales per order
 
$
52.47
     
(5.6)%
 
 
$
55.58
 

 
 
 
 
 
- 13 -

 
 
 
 
Revenues for the three months ended March 31, 2012 grew to $3,153,607 from $2,284,552 for the three months ended March 31, 2011. Revenues increased for the three months ended March 31, 2012 compared to the prior year as a result of an increase in order volume.  This increase is due primarily to a sharp increase in prescription products and an increase in both over the counter products and freight revenue. During the three months ended March 31, 2012, revenues from the Hocks acquisition totaled $597,279 compared to the three months ended March 31, 2011 of $636,204. The $869,055 increase in revenues for the three months ended March 31, 2012 compared to the three months ended March 31, 2011 was due primarily to increased advertising.

Another indicator of increased business activity was that our website attracted over 1,087,853 visits with over 3,541,872 pageviews during the three months ended March 31, 2012 compared to 837,020 visits and 2,901,173 pageviews during the three months ended March 31, 2011.
 
Cost of Sales and Gross Margin
  
   
The three months
ended
March 31, 2012
   
%
Change
   
The three months
ended
March 31, 2011
 
Total cost of sales
 
$
1,704,647
     
31.3%
   
$
1,298,143
 
Total gross profit dollars
 
$
1,448,960
     
46.9%
   
$
986,409
 
Total gross margin percentage
   
45.9
%    
2.7%
     
43.2
 %
 
Total cost of sales increased to $1,704,647 for the three months ended March 31, 2012 as compared to $1,298,143 for the three months ended March 31, 2011 as a result of growth in order volume and revenue. Gross margin percentage increased year-over-year from 43.2% for the year ended March 31, 2011 to 45.9% for the three months ended March 31, 2012. The increase in gross profit margins was due primarily to the product mix shifting to primarily prescription drugs sales compared to over the counter products.
 
Selling, General and Administrative Expenses
 
   
The three months
ended
March 31, 2012
   
%
Change
   
The three months
ended
March 31, 2011
Selling, general and administrative expenses
 
$
2,684,478
     
37.4%
   
$
1,953,698
 
Percentage of revenue
   
85.1%
     
(0.4)%
     
85.5%
 

Selling, general and administrative expenses increased by $730,780 in the three months ended March 31, 2012 compared to the same period in 2011, an increase of 37.4%.  During the three months ended March 31, 2012, expense increases were due primarily to increased headcount and salary related expenses of $94,562 and increases of approximately $490,642 for advertising, credit card fees, finance charge, promotional, shipping and fulfillment and professional expenses compared to the three months ended March 31, 2011. In addition, the following expenses increased for the three months ended March 31, 2012 compared to the three months ended March 31, 2011: (a) $259,409 for non-cash stock based compensation expense compared to $211,713, (b) and depreciation and amortization expenses of $111,851 compared to $71,008.

Other income (expense)

   
The three months
ended
March 31, 2012
   
%
Change
   
The three months
ended
March 31, 2011
 
Interest income
    2,548       119.2 %     1,162  
Interest expense
    317,342       201.8 %     105,152  
 
 
 
 
 
 
- 14 -

 
 
 

 
Interest expense increased from $105,152 in the three months ended March 31, 2011 to $317,342 in the three months ended March 31, 2012, primarily due to the recognition of the non-cash accretion of debt discount for the three months ended March 31, 2012 of $215,711 compared to $86,775 for the same period in 2011. Contractual loan interest expense increased from $101,631 for the three months ended March 31, 2012 compared to $18,377 in the three months ended March 31, 2011.

 Off-Balance Sheet Arrangements
 
We have not entered into any transactions with unconsolidated entities in which we have financial guarantees, subordinated retained interests, derivative instruments or other contingent arrangements that expose us to material continuing risks, contingent liabilities or any other obligations under a variable interest in an unconsolidated entity that provides us with financing, liquidity, market risk or credit risk support.
 
Impact of Inflation
 
We believe that inflation has not had a material impact on our results of operations for the three months ended March 31, 2012 and 2011. We cannot assure you that future inflation will not have an adverse impact on our operating results and financial condition.
 
            Liquidity and Capital Resources
 
As of March 31, 2012, the Company had negligible cash and a working capital deficit of $4,479,571.  During the three months ended March 31, 2012, the Company generated revenue of $3,153,607 and a net loss of $1,550,312.  For the three months ended March 31, 2012, cash flows included net cash used in operating activities of $177,395, net cash used in investing activities of $81,043 and net cash provided by investing activities of $258,401.

Since inception, the Company has financed its operations primarily through product sales to customers, and debt and private equity investments by existing stockholders, officers and directors.  Our sources and uses of funds during this period were as follows:
 
For the three months ended March 31, 2012, cash flows included net cash used in operating activities of $177,395.  The primary reason for the use of cash was due to the increase in net loss for the period for the expansion of the Company’s operating expenses to support increased revenues offset in part by accounts payable-trade of $550,400, stock-based compensation of $259,409, amortization of deferred debt discount of $215,711, and accrued expenses and other current liabilities of $84,793. Management believes that during the current year with the organic growth that the losses will decline, although there can be no such assurance.
 
For the three months ended March 31, 2012, net cash used in investing activities was $81,043. For the three months ended March 31, 2011, net cash used in investing activities was $221,407.
 
For the three months ended March 31, 2012, net cash provided by financing activities was $258,401, due primarily to advances from certain stockholders of $375,000, of which $63,812 has been repaid to certain stockholders and proceeds from shares issued of $125,000 offset in part by capital lease payments of $22,131 and a cash overdraft of $155,656. For the three months ended March 31, 2011, no cash was provided by financing activities.

Management believes that the Company has taken certain steps to improve its operations and cash flows, including improved inventory management and an increase in the number of suppliers. The acquisition of Hocks.com in February 2011 should continue to improve the operating productivity and efficiency of the Company’s expenditures for selling, general and administrative activities during 2012.  Management believes that this plan will be successful, but there are no such assurances.
 
 
 
 
 
 
- 15 -

 
 
 

 
Subsequent to March 31, 2012, the Company received advances from certain stockholders aggregating $220,000 which has been repaid as of the date of this report and the repayment of employee advances aggregating $235,000. In addition, the Company received proceeds from the sale of common stock in the amount of $300,004 and from the exercise of stock options in the amount of $26,662. However, there is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company and whether the Company will be able to turn into a profitable position and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to develop and implement a plan to extend payables and reduce overhead until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful.

These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Notwithstanding the foregoing, the accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern and the realization of assets and the satisfaction of liabilities in the normal course of business.  The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values.  The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
 
Critical Accounting Policies and Estimates
 
The preparation of our condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires our management to exercise its judgment. We exercise considerable judgment with respect to establishing sound accounting policies and in making estimates and assumptions that affect the reported amounts of our assets and liabilities, our recognition of revenues and expenses, and disclosures of commitments and contingencies at the date of the financial statements. Our significant estimates include reserves related to accounts receivable and inventory, the recoverability and useful lives of long-lived assets, the valuation allowance related to deferred tax assets, the valuation of equity instruments and debt discounts.  

On an ongoing basis, we evaluate our estimates and judgments. We base our estimates and judgments on a variety of factors including our historical experience, knowledge of our business and industry, current and expected economic conditions, the composition of our products/services and the regulatory environment.  We periodically re-evaluate our estimates and assumptions with respect to these judgments and modify our approach when circumstances indicate that modifications are necessary.
 
While we believe that the factors we evaluate provide us with a meaningful basis for establishing and applying sound accounting policies, we cannot guarantee that the results will always be accurate.   Since the determination of these estimates requires the exercise of judgment, actual results could differ from such estimates.
 
We account for stock-based compensation in accordance with the fair value recognition provisions of Accounting Standards Codification (“ASC”) 718, for all stock-based payment awards is based on the estimated grant-date fair value. We recognize these compensation costs over the requisite service period of the award, which is generally the option vesting term.  Option valuation models require the input of highly subjective assumptions including the expected life of the option. During the period ended June 30, 2011 and prior periods, the fair value of stock-based payment awards was estimated using the Black-Scholes option model with a volatility figure derived from an index of historical stock prices of comparable entities until sufficient data existed to estimate the volatility using the Company’s own historical stock prices.  Beginning July 2011, we began to use the historical trading prices of its own common stock as a component in the calculation of an estimated volatility figure to determine the fair value of stock-based payment awards using the Black-Scholes model. Management determined this assumption to be a better indicator of value. We account for the expected life of options in accordance with the “simplified” method provisions of SEC Staff Accounting Bulletin (“SAB”) No. 110, which enables the use of the simplified method for “plain vanilla” share options as defined in SAB No. 107.
 
 
 
 
 
 
- 16 -

 
 
 
 
 

Not required.


Evaluation of Disclosure Controls and Procedures
 
Disclosure controls and procedures (as defined in Rules 13a-15 (e) and 15d–15(e) under the Exchange Act) are designed to provide reasonable assurance that information required to be disclosed in reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the forms and rules of the SEC and that such information is accumulated and communicated to management, including the CEO and CFO, in a manner to allow timely decisions regarding required disclosures.
 
In connection with the preparation of this Form 10–Q, our management, including the CEO and CFO, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2012. As described below, management has identified material weaknesses in our internal control over financial reporting, which is an integral component of our disclosure controls and procedures. As a result of those material weaknesses, our management has concluded that, as of March 31, 2012 our disclosure controls and procedures were not effective.
 
Internal Control over Financial Reporting
 
Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined In Exchange Act Rule 13a-15(f).  The term “internal control over financial reporting” is defined as a process designed by, or under the supervision of, the registrant’s principal executive and principal financial officers, or persons performing similar functions, and effected by the registrant’s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:
 
·
pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the registrant;
 
·
provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the registrant are being made only in accordance with authorizations of management and directors of the registrant; and
 
·
provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the registrant’s assets that could have a material effect on the financial statements.
 
Our internal control system is designed to provide reasonable assurance to our management and board of directors regarding the preparation and fair presentation of published financial statements. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs.  In addition, because of changes in conditions, the effectiveness of internal control may vary over time.
 
 
 
 
 
 
- 17 -

 
 
 
 
 
As of December 31, 2011, management conducted an evaluation of the effectiveness of the Company’s internal control over financial reporting based on the criteria in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) and identified the material weaknesses described below. In conducting this evaluation, management took into account the information identified and conclusions reached by the non-management directors in the Review.  As of March 31, 2012, management has concluded that the material weaknesses it identified, continued to exist and that the Company’s internal control over financial reporting was not effective as of March 31, 2012. A “material weakness” is a significant deficiency, or combination of significant deficiencies, that results in more than a remote likelihood that a material misstatement of our annual or interim financial statement will not be presented or detected by our employees.
 
The specific material weaknesses that management identified in our internal controls as of March 31, 2012 are as follows:
 
·
We did not develop appropriate accounting policies and procedures, including the review and supervision, for all necessary areas and did not effectively communicate our existing policies to our employees.
 
·
We did not have a sufficient number of adequately trained technical accounting and external reporting personnel to support standalone external financial reporting under OTCQB or SEC requirements.
 
·
We did not have personnel with sufficient experience with United States generally accepted accounting principles to address complex transactions.
 
·
We did not have effective controls over disbursements to assure that disbursements were properly authorized and recorded.
 
·
We did not maintain a fully integrated financial consolidation and reporting system throughout the year and as a result, extensive manual analysis, reconciliation and adjustments were required in order to produce financial statements for external reporting purposes.
 
·
We did not appropriately segregate employees’ duties in connection with the review and approval of certain transactions, reconciliations and other processes in day-to-day operations.
 
·
We did not have effective policies and procedures to ensure that senior management and the Board of Directors would receive timely information about related party transactions.
 
Plans For Remediation of Material Weaknesses

We are in the process of implementing changes to strengthen our internal controls.  We are in the process of developing a remediation plan for the identified material weaknesses and we expect that work on the plan will continue throughout 2012.  Specifically, to address the material weaknesses arising from insufficient accounting personnel, the Company removed one member of the accounting staff who was determined not to have sufficient accounting expertise, and the Company planned to (i) hire a full-time Chief Financial Officer who will be on-site throughout the year and (ii) hire two additional full-time accounting personnel during 2012. As of August 20, 2012, the Company has engaged one of the two additional accounting personnel.  To address the material weakness arising from inadequate control over disbursements, the Company has canceled certain credit cards, limited the number of personnel with authority over the Company's bank accounts and is in the process of revising its policies and procedures for review and approval of employee disbursements and expenses.  The Company is currently evaluating what additional policies and procedures may be necessary, how to most effectively communicate the policies and procedures to its personnel and how to improve the integration of its financial consolidation and reporting system.  Where appropriate, the Company is receiving advice and assistance from the third-party experts as it implements and refines its remediation plan.
 
 
 
 
 
 
 
- 18 -

 
 
 
 
Additional measures may be necessary, and the measures we expect to take to improve our internal controls may not be sufficient to address the issues identified, to ensure that our internal controls are effective or to ensure that such material weakness or other material weaknesses would not result in a material misstatement of our annual or interim financial statements. In addition, other material weaknesses or significant deficiencies may be identified in the future. If we are unable to correct deficiencies in internal controls in a timely manner, our ability to record, process, summarize and report financial information accurately and within the time periods specified in the rules and forms of the SEC will be adversely affected. This failure could negatively affect the market price and trading liquidity of our common stock, cause investors to lose confidence in our reported financial information, subject us to civil and criminal investigations and penalties, and generally materially and adversely impact our business and financial condition.
 
           Changes in Internal Control Over Financial Reporting
 
           There were no changes in our internal control over financial reporting or in other factors during the quarter ended March 31, 2012, that have materially affected, or were reasonably likely to materially affect, our internal control over financial reporting. The Company believes that the implementation of plans for remediation of material weaknesses, referenced in the above section, will have additional benefits of improving internal controls over financial reporting. The Company is a non-accelerated filer and is not subject to Section 404(b) of the Sarbanes Oxley Act. As discussed above, subsequent to March 31, 2012, the Company hired temporary personnel and a consulting group to assist with its financial reporting process.

 
 
 
 
 
 
 
 
 

 
 
- 19 -




PART II. OTHER INFORMATION


In the ordinary course of business, we may become subject to lawsuits and other claims and proceedings.  Such matters are subject to uncertainty and outcomes are often not predictable with assurance.  Our management does not presently expect that any such matters will have a material adverse effect on the Company’s financial condition or results of operations.  We are not currently involved in any pending or threatened material litigation or other material legal proceedings.


Not required.


On July 16, 2012, the Company issued 11,112 shares of common stock at a per share price of $4.50 to one accredited investor in a private offering. The sale of the common stock was made without registration in reliance on the exemption from registration afforded by Section 4(2) of the Securities Act of 1933 and corresponding provisions of state securities laws, which exempt transactions by an issuer not involving any public offering.

On August 10, 2012, the Company issued an aggregate of 22,222 shares of common stock at a per share price of $4.50 to two accredited investor in a private offering. The sale of the common stock was made without registration in reliance on the exemption from registration afforded by Section 4(2) of the Securities Act of 1933 and corresponding provisions of state securities laws, which exempt transactions by an issuer not involving any public offering.


None.


None.


None.
 

The following exhibits are filed as part of this quarterly report:
 
Exhibit Number
 
 Description
     
31.1
 
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act.
     
31.2
 
Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act.
     
32.1
 
Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act.
     
32.2
 
Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act.
 
 


 
 
- 20 -



 
 
 
In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
Dated:   September 5, 2012
 
 
HEALTHWAREHOUSE.COM, INC.
 
 
By:  /s/ Lalit Dhadphale                                                        
    Lalit Dhadphale
    President and Chief Executive Officer
    (principal executive officer)
 
 
By: /s/  Patrick E. Delaney                                                    
    Patrick E. Delaney
    Chief Financial Officer and Treasurer
    (principal financial and accounting officer)

 
 
 
 
 



 
- 21 -


 
 
 
 
Exhibit Index
 

 
 
 
 
 
 
 
 


 
- 22 -

 

 
 

PINX:HEWA Quarterly Report 10-Q Filling

PINX:HEWA Stock - Get Quarterly Report SEC Filing of PINX:HEWA stocks, including company profile, shares outstanding, strategy, business segments, operations, officers, consolidated financial statements, financial notes and ownership information.

PINX:HEWA Quarterly Report 10-Q Filing - 3/31/2012
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Title |  Date |  Company |  Symbol |  Interest |  Popularity

Previous: PINX:HEWA Insider Activity 4 Filing - 9/26/2012  |  Next: PINX:HICKA Insider Activity 3 Filing - 3/7/2012